The stock saw a sharp upmove of 300 percent between March 2020 and July 2021, touching Rs 1,800 as COVID outbreak led to a spike in demand for its main offerings — Ibuprofen, Favipiravir and Gabapentin
The stock saw a sharp upmove of 300 percent between March 2020 and July 2021, touching Rs 1,800 as COVID outbreak led to a spike in demand for its main offerings — Ibuprofen, Favipiravir and Gabapentin The stock saw a sharp upmove of 300 percent between March 2020 and July 2021, touching Rs 1,800 as COVID outbreak led to a spike in demand for its main offerings — Ibuprofen, Favipiravir and Gabapentin Moneycontrol Latest News Read More
हिन्दी 
English